HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Clinicopathologic Analysis of Primary Adrenal Diffuse Large B-Cell Lymphoma: A Reappraisal of 23 Japanese Patients Based on EBV Association and PD-L1 Expression in Tumor Cells.

Abstract
Primary adrenal diffuse large B-cell lymphoma (PA-DLBCL) is rare. We investigate 23 Japanese patients with PA-DLBCL to understand the clinicopathologic features and biological behavior of this disease. The 17 males and 6 females had a median age of 74 years (range: 40 to 86 y). Tumor cells harbored Epstein-Barr virus-encoded small RNA (EBER) in 9 (39%) samples, including samples from the 2 patients with methotrexate-associated B-cell lymphoproliferative disorder. Programmed cell death ligand 1 (PD-L1) expression was detected in tumor cells of 6 (26%) samples, including 1 EBER+ and 5 EBER- samples. Four (17%) patients exhibited an intravascular proliferating pattern, and all 4 patient samples showed positive staining for PD-L1 in tumor cells. Among those patients, 3 showed intravascular proliferating pattern accompanied by a diffuse extravascular proliferation of tumor cells, and 1 patient was diagnosed with intravascular large B-cell lymphoma. We divided the 23 patients into 3 groups: EBER+ (n=9, 39%), EBER-PD-L1+ (n=5, 22%), and EBER-PD-L1- (n=9, 39%). A comparison of the outcomes among the 3 groups showed significant differences in overall survival (P=0.034). The EBER+ group had the worst prognosis, and the EBER-PD-L1- group had the best prognosis. We also compared the outcomes among the 3 groups that received rituximab-containing chemotherapies. Both the overall survival and progression-free survival were significantly different among these groups (P<0.001 and P=0.002, respectively). In conclusion, we evaluated 3 types of PA-DLBCL and found that each had unique clinical, pathologic, and prognostic features. Our results suggested that immune senescence, iatrogenic immunodeficiency, and immune evasion contribute to the development of PA-DLBCL.
AuthorsTasuku Kawano, Yuta Tsuyuki, Yuka Suzuki, Kazuyuki Shimada, Seiichi Kato, Taishi Takahara, Mayuko Mori, Masato Nakaguro, Ayako Sakakibara, Shigeo Nakamura, Akira Satou
JournalThe American journal of surgical pathology (Am J Surg Pathol) Vol. 45 Issue 12 Pg. 1606-1615 (12 01 2021) ISSN: 1532-0979 [Electronic] United States
PMID34534136 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
CopyrightCopyright © 2021 Wolters Kluwer Health, Inc. All rights reserved.
Chemical References
  • B7-H1 Antigen
  • Biomarkers, Tumor
  • CD274 protein, human
  • RNA, Viral
  • Rituximab
Topics
  • Adrenal Gland Neoplasms (immunology, pathology, therapy, virology)
  • Adrenalectomy
  • Adult
  • Aged
  • Aged, 80 and over
  • Antineoplastic Combined Chemotherapy Protocols (therapeutic use)
  • B7-H1 Antigen (analysis)
  • Biomarkers, Tumor (analysis)
  • Epstein-Barr Virus Infections (immunology, pathology, therapy, virology)
  • Female
  • Herpesvirus 4, Human (genetics)
  • Humans
  • Japan
  • Lymphoma, Large B-Cell, Diffuse (immunology, pathology, therapy, virology)
  • Male
  • Middle Aged
  • Progression-Free Survival
  • RNA, Viral (genetics)
  • Retrospective Studies
  • Risk Factors
  • Rituximab (therapeutic use)
  • Time Factors

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: